Skip to main content
Journal cover image

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Publication ,  Journal Article
Desjardins, A; Quinn, JA; Vredenburgh, JJ; Sathornsumetee, S; Friedman, AH; Herndon, JE; McLendon, RE; Provenzale, JM; Rich, JN; Sampson, JH ...
Published in: J Neurooncol
May 2007

PURPOSE: Recent reports demonstrate the activity of imatinib mesylate, an ATP-mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme. We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG). PATIENTS AND METHOD: Patients with grade III MG at any recurrence, received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule. The imatinib mesylate dose was 500 mg twice a day for patients on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs. Clinical assessments were performed monthly and radiographic assessments were obtained at least every 2 months. The primary endpoint was 6-month progression-free survival (PFS) rate. RESULTS: Thirty-nine patients were enrolled. All patients had progressive disease after prior radiotherapy and at least temozolomide-based chemotherapy. The median number of episodes of prior progression was 2 (range, 1-7) and the median number of prior treatment regimens was 3 (range, 1-8). With a median follow-up of 82.9 weeks, 24% of patients were progression-free at 6 months. The radiographic response rate was 10%, while 33% achieved stable disease. Among patients who achieved at least stable disease at first evaluation, the 6-month and 12-month PFS rates were 53% and 29%, respectively. The most common grade 3 or greater toxicities were hematologic and complicated less than 4% of administered courses. CONCLUSION: Imatinib mesylate plus hydroxyurea, is well tolerated and associated with anti-tumor activity in some patients with recurrent grade 3 MG.

Duke Scholars

Published In

J Neurooncol

DOI

ISSN

0167-594X

Publication Date

May 2007

Volume

83

Issue

1

Start / End Page

53 / 60

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Pyrimidines
  • Prognosis
  • Piperazines
  • Oncology & Carcinogenesis
  • Oligodendroglioma
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Imatinib Mesylate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Quinn, J. A., Vredenburgh, J. J., Sathornsumetee, S., Friedman, A. H., Herndon, J. E., … Reardon, D. A. (2007). Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol, 83(1), 53–60. https://doi.org/10.1007/s11060-006-9302-2
Desjardins, Annick, Jennifer A. Quinn, James J. Vredenburgh, Sith Sathornsumetee, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.J Neurooncol 83, no. 1 (May 2007): 53–60. https://doi.org/10.1007/s11060-006-9302-2.
Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007 May;83(1):53–60.
Desjardins, Annick, et al. “Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.J Neurooncol, vol. 83, no. 1, May 2007, pp. 53–60. Pubmed, doi:10.1007/s11060-006-9302-2.
Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007 May;83(1):53–60.
Journal cover image

Published In

J Neurooncol

DOI

ISSN

0167-594X

Publication Date

May 2007

Volume

83

Issue

1

Start / End Page

53 / 60

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Pyrimidines
  • Prognosis
  • Piperazines
  • Oncology & Carcinogenesis
  • Oligodendroglioma
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Imatinib Mesylate